Doxorubicin pathways: Pharmacodynamics and adverse effects

Pharmacogenetics and Genomics

Volumn 21, Issue 7, 2011, Pages 440-446

  Thorn, Caroline F ^a   Oshiro, Connie ^a   Marsh, Sharon ^c   Hernandez Boussard, Tina ^a   McLeod, Howard ^b   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ABCC1; ABCC2; anthracyclines; cardiotoxicity; CAT; CBR3; CYBA; doxorubicin; drug resistance; NCF4; pharmacogenomics; PharmGKBpathways; RAC2

Indexed keywords

CYCLOSPORIN; DAUNORUBICIN; DEFERASIROX; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PHENYTOIN; RAZOXANE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; DRUG MECHANISM; GENE AMPLIFICATION; HUMAN; NEOPLASM; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL;

EID: 79959805353     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833ffb56     Document Type: Article

References (62)

1. Lal S, Mahajan A, Chen WN, Chowbay B. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 2010; 11:115-128.
2. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61:154-171.
3. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 2009; 16:1656-1672.
4. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009; 16:3267-3285.
5. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. Adriamycin, 14-hydroxydaunomycin: a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969; 11:1101-1110.
6. Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007; 7:56-60. (Pubitemid 47339867)
7. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19:670-686. (Pubitemid 23004844)
8. Swain SM,Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869-2879. (Pubitemid 36605157)
9. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-741. (Pubitemid 29094544)
10. Doroshow JH. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci USA 1986; 83:4514-4518. (Pubitemid 16057079)
11. Pawlowska J, Tarasiuk J,Wolf CR, Paine MJ, Borowski E. Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res 2003; 13:245-252. (Pubitemid 38166378)
12. Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 2004; 18:664-675. (Pubitemid 38451788)
13. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase-II. Science 1984; 226:466-468. (Pubitemid 14012819)
14. Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A. The role of topoisomerase-IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev 2009; 35:662-667.
15. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001; 93:571-576. (Pubitemid 32701417)
16. Robles AI, Wang XW, Harris CC. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53- mediated apoptotic cell death. Oncogene 1999; 18:4681-4688. (Pubitemid 29417743)
17. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G. Doxorubicin cardiotoxicity and the control of iron metabolism: quinonedependent and independent mechanisms. Methods Enzymol 2004; 378:340-361.
18. Wallace KB. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 2007; 7:101-107. (Pubitemid 47339855)
19. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15:1318-1332. (Pubitemid 27167363)
20. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112:3754-3762. (Pubitemid 43739516)
21. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009; 23:1118-1126.
22. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 1998; 12:541-552. (Pubitemid 28183513)
23. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 1988; 85:3585-3589.
24. Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 2000; 294:396-401. (Pubitemid 30434713)
25. Clementi ME, Giardina B, Di Stasio E, Mordente A, Misiti F. Doxorubicinderived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res 2003; 23:2445-2450. (Pubitemid 36897113)
26. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 2003; 35:1469-1479. (Pubitemid 37452472)
27. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase-IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67:8839-8846. (Pubitemid 47437460)
28. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; 5:CD005006.
29. Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol 2007; 23:27-37. (Pubitemid 44950186)
30. Platel D, Pouna P, Bonoron-Adele S, Robert J. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anti-cancer Drugs 1999; 10:671-676. (Pubitemid 29450209)
31. Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988; 43:372-375.
32. Cusack BJ, Tesnohlidek DA, Loseke VL, Vestal RE, Brenner DE, Olson RD. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 1988; 22: 294-298.
33. Colombo T, Zucchetti M, D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 1994; 269:22-27. (Pubitemid 24143229)
34. Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Rao Lelsani PC, et al. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer 2010; 126:1327-1338.
35. Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007; 7:67-71. (Pubitemid 47339869)
36. Kaye S, Merry S. Tumour cell resistance to anthracyclines: a review. Cancer Chemother Pharmacol 1985; 14:96-103. (Pubitemid 15164806)
37. Germann UA. P-glycoprotein: a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996; 32A:927-944.
38. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258:1650-1654. (Pubitemid 23012438)
39. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001; 7:1798-1804. (Pubitemid 32708651)
40. Singhal SS, Singhal J, Sharma R, Singh SV, Zimniak P, Awasthi YC, et al. Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistances in lung cancer cells. Int J Oncol 2003; 22:365-375.
41. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 2008; 105:9053-9058.
42. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008; 26:736-744. (Pubitemid 351264386)
43. Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, et al. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 1990; 27:219-225.
44. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745-749. (Pubitemid 14248398)
45. Lal S,Wong ZW, Sandanaraj E, Xiang X, Ang PC, Lee EJ, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99:816-823. (Pubitemid 351448088)
46. Jeong H, Herskowitz I, Kroetz DL, Rine J. Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet 2007; 3:e39.
47. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 2001; 46: 656-663. (Pubitemid 33134743)
48. Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, Schrenk D, et al. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 2002; 12:321-330. (Pubitemid 34620660)
49. Yin JY, Huang Q, Yang Y, Zhang JT, Zhong MZ, Zhou HH, et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 2009; 19:206-216.
50. Rajic V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric- Rascan I, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009; 50:1693-1698.
51. Bains OS, Karkling MJ, Grigliatti TA, Reid RE, Riggs KW. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in-vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 2009; 37:1107-1114.
52. Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99: 2045-2054.
53. Gonzalez-Covarrubias V, Zhang J, Kalabus JL, Relling MV, Blanco JG. Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos 2009; 37:400-407.
54. Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 2008; 18:621-631.
55. Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW. Naturally occurring variants of human CBR3 alter anthracycline in-vitro metabolism. J Pharmacol Exp Ther 2010; 332:755-763.
56. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene, NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008; 112:2789-2795. (Pubitemid 351969225)
57. Lakhman SS, Ghosh D, Blanco JG. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 2005; 33:254-257. (Pubitemid 40220348)
58. Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, et al. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res 2009; 15:5258-5266.
59. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DTdiaphorase), functions and pharmacogenetics. Methods Enzymol 2004; 382:115-144. (Pubitemid 38240788)
60. Sandanaraj E, Lal S, Selvarajan V, Ooi LL,Wong ZW,Wong NS, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 2008; 14:7116-7126.
61. Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 2007; 8:567-575. (Pubitemid 46939582)
62. Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW. Naturally occurring variants of human CBR3 alter anthracycline in-vitro metabolism. J Pharmacol Exp Ther 2010; 332:755-763.